Contents lists available at ScienceDirect

European Journal of Medicinal Chemistry

journal homepage: http://www.elsevier.com/locate/ejmech

Original article

Inhibitors of human neutrophil elastase based on a highly functionalized *N*-amino-4-imidazolidinone scaffold

Guijia He, Dengfeng Dou, Liuqing Wei, Kevin R. Alliston, William C. Groutas*

Department of Chemistry, Wichita State University, 206 McKinley Hall, 1845 Fairmount, Wichita, Kansas 67260, USA

A R T I C L E I N F O

Article history: Received 9 February 2010 Received in revised form 17 May 2010 Accepted 18 June 2010 Available online 30 June 2010

Keywords: Protease inhibitors Neutrophil elastase

ABSTRACT

A series of compounds based on the *N*-amino-4-imidazolidinone scaffold was synthesized and screened against human neutrophil elastase (HNE). These studies lead to the identification of a selective, low micromolar reversible competitive inhibitor of HNE.

© 2010 Elsevier Masson SAS. All rights reserved.

雨

1. Introduction

Chronic obstructive pulmonary disease (COPD) is a major health problem that affects more than 16 million people in the U.S. [1]. The disorder is associated with airflow limitation that is not easily reversible [2,3]. Currently, there are no drugs on the market for the specific treatment of COPD.

Although the pathogenesis of COPD is poorly understood, the disorder is characterized by increased numbers of alveolar macrophages, neutrophils and cytotoxic T lymphocytes, increased elastolysis by an array of proteases [4], oxidative stress [5], apoptosis [6], and the release of multiple inflammatory mediators, including cytokines and chemokines [7–10].

Several lines of evidence suggest that macrophage- and neutrophil-derived oxidative and proteolytic mediators released at sites of inflammation play an important role in the pathophysiology of COPD [11]. Most prominent among these mediators are human neutrophil elastase (HNE), proteinase 3 (Pr 3), and MMP-12. Elucidation of the biochemical and molecular mechanisms related to the pathophysiology of COPD may lead to the emergence of effective therapeutics [11].

HNE and Pr 3 show significant differences in their S_2 and $S_1'-S_3'$ subsites [12]. For instance, the $S_1'-S_3'$ pockets in Pr 3 are smaller and more polar than those of HNE because of the presence of Asp61 and Arg143 [13]. These differences can be exploited by utilizing

a scaffold that docks to the active site in a predictable fashion and orients appended recognition elements toward the S' subsites. Thus, based on previous studies involving the use of functionalized 4-imidazolidinone derivatives as reversible competitive inhibitors of HNE [14], we reasoned that inhibitors based on the *N*-amino-4-imidazolidinone scaffold (I) (Fig. 1) may exhibit high selectivity toward HNE over Pr 3 (and vice versa) through exploitation of differences in the S' subsites of the two enzymes. We describe herein the results of exploratory studies related to the selective inhibition of HNE by derivatives based on scaffold (I) (Fig. 1).

2. Chemistry

The desired compounds 7-13, 14-18 and 19-26 were synthesized as shown in Scheme 1. Cbz-DL-phenylalanine (or Cbz-DLleucine) was coupled to t-butyl carbazate using isobutyl chloroformate in the presence of *N*-methylmorpholine. Removal of the protective group followed by sodium triacetoxyborohydridemediated reductive amination [15] yielded intermediate 3 which was cyclized with aqueous formaldehyde. The formation of the 4-imidazolidinone ring was also accompanied by N-hydroxymethylation of the product to afford compound 4. Stirring compound 4 with aqueous sodium hydroxide resulted in clean removal of the hydroxymethyl moiety to yield the desired intermediate 5. Initial attempts at removing the Boc group using trifluoroacetic acid or dry HCl lead to intractable mixtures, however, microwave irradiation of 5 in the presence of silica gel [16] yielded the desired N-amino-4-imidazolidinone which could be functionalized via reaction with an array of structurally-diverse isocyanates,



^{*} Corresponding author. Tel.: +1 316 978 7374; fax: +1 316 978 3431. *E-mail address*: bill.groutas@wichita.edu (W.C. Groutas).

^{0223-5234/\$ –} see front matter @ 2010 Elsevier Masson SAS. All rights reserved. doi:10.1016/j.ejmech.2010.06.028



Fig. 1. General structure of inhibitor (I).

carboxylic acids, acid anhydrides, sulfonyl chlorides or *N*-protected amino acids. The resulting products could be readily debenzylated using catalytic hydrogenation.

3. Biochemical studies

Enzyme assays and inhibition studies using neutrophil elastase and proteinase 3 were conducted as previously described [17]. The inhibition constant (K_I) of compound **24** was determined using a Dixon plot [18].

4. Results and discussion

4.1. Inhibitor design rationale

The design of inhibitor (I) was based on the following considerations: (a) recent studies in our laboratory have demonstrated that inhibitor (II) (Fig. 2) is a highly efficient mechanism-based irreversible inhibitor of serine proteases that docks to the active site of HNE with the R_1 and R_2 groups occupying the S_1 and S_2 subsites [13]; (b) replacement of the sulfonyl group with a methylene group lowers the reactivity of the amide carbonyl in the resulting 4-imidazolidinone ring making possible the transformation of irreversible inhibitor (II) into reversible competitive inhibitor (III)(Fig. 2) [14]; (c) groups R₄ and R₅ in (I) are oriented toward the S' subsites; (d) HNE is a basic, 218 amino acid single polypeptide glycoprotein whose primary structure shows considerable homology (54%) [13] with Pr 3. Furthermore, the two enzymes have extended binding sites and show a preference for hydrophobic substrates/inhibitors. However, although HNE and Pr 3 exhibit high sequence identity, their S' subsites show significant differences which can be exploited [13,19]. As mentioned earlier, the S₁'-S₃' pockets in Pr 3 are smaller and more polar than those of HNE because of the presence of Asp61 and Arg143 while the presence of Val190, Phe192, Ala213, Val216, Phe228 and the disulfide bridge Cys191–Cys220 makes the active site of HNE hemispherical and hydrophobic.

Based on the aforementioned considerations, it was envisaged that derivatives based on scaffold (I) might make possible the attainment of optimal potency and selectivity toward HNE (or Pr 3) through favorable binding interactions with the S' subsites of the two enzymes. Thus, initial exploratory studies focused on generating a series of focused libraries by varying diversity sites R4 and R₅. All compounds were derived from (DL) Phe ($P_1 = benzyl$) and (DL) Leu (P_1 = isobutyl) and listed in Table 1. The inhibitory activity against HNE and Pr 3 is summarized in Fig. 3. Compound 24 was found to be a highly selective, low micromolar (K_I 7.34 μ M) reversible competitive inhibitor of HNE, as evidenced by the construction of a Dixon plot [18] (Fig. 4). Compound 24 was devoid of any inhibitory activity toward Pr 3 while the rest of the compounds showed minimal inhibition (0-20%) toward both enzymes (Fig. 3). Inhibition of HNE and Pr 3 appears to be insensitive to variations in the structural diversity of R₄ and R₅, suggesting that R₄ and R₅ are oriented toward the S' subsites in a nonoptimal manner. The results also suggest that it may be possible to design non-covalent inhibitors of HNE and Pr 3 that exhibit optimized potency and selectivity through the utilization of appropriate recognition elements. These inhibitors are unlike most



Scheme 1. General synthesis of inhibitor I. Reagents and conditions: a) IBCF/NMM THF then NH₂NHBoc; b) H₂/10%Pd-C/CH₃OH; c) RCHO/NaBH(OAc)₃/HOAc; d) HCHO or R₃CHO; e) NaOH/aq dioxane; f) silica gel/microwave; g) RSO₂Cl/base or RN=C=O or (RCO)₂O or RCOOH/EDCI/DMF or protected amino acid/EDCI/DMF.



Fig. 2. Design rationale of reversible competitive inhibitors of human neutrophil elastase and proteinase 3.

reported inhibitors of mammalian and viral serine proteases which incorporate in their structures a warhead that leads to covalent inhibition or, in the case of transition state inhibitors, the formation of a reversible covalent adduct [20].

In conclusion, we have demonstrated that the multiple points of diversity afforded by scaffold (I) render it well-suited to the design of non-covalent inhibitors of serine proteases with similar active sites.

5. Experimental section

5.1. General methods

The ¹H spectra were recorded on a Varian XL-300 or XL-400 NMR spectrometer. A Hewlett-Packard diode array UV/Vis spectrophotometer was used in the *in vitro* evaluation of the inhibitors. Human neutrophil elastase, proteinase 3 and Boc-Ala-Ala-Nva thiobenzvl ester were purchased from Elastin Products Company. Owensville, MO. Methoxysuccinyl-Ala-Ala-Pro-Val p-nitroanilide and 5,5'-dithiobis (2-nitrobenzoic acid) were purchased from Sigma Chemicals, St. Louis, MO. Melting points were determined on a Mel-Temp apparatus and are uncorrected. Reagents and solvents were purchased from various chemical suppliers (Aldrich, Acros Organics, TCI American, and Bachem). Silica gel (230-450 mesh) used for flash chromatography was purchased from Sorbent Technologies (Atlanta, GA). Thin layer chromatography was performed using Analtech silica gel plates and the TLC plates were visualized using iodine and/or UV light. All compounds synthesized as diastereomeric mixtures were screened against human neutrophil elastase and proteinase 3 as such without separating the individual diastereomers.

5.2. Representative syntheses

5.2.1. (RS)-tert-Butyl 2-(2-(benzyloxycarbonylamino)-3-phenylpropanoyl)hydrazine-carboxyl-ate **1**

A solution of Z-DL-Phe-OH (71.84 g, 240 mmol) in dry THF (200 mL) cooled in an ice-bath was treated with isobutyl chloroformate (32.78 g; 240 mmol), followed with *N*-methylmorpholine (24.28 g; 240 mmol). The resulting mixture was stirred for 5 min, and t-butyl carbazate (31.60 g; 240 mmol) was added. The ice-bath was removed and the reaction mixture was stirred for 7 h at room temperature. The solvent was removed on the rotary evaporator and the residue was taken up in methylene chloride (200 mL). The resulting solution was washed sequentially with 5% aqueous HCl (70 mL), 5% aqueous NaHCO₃ (3 × 70 mL) and brine (3 × 70 mL). The organic phase was dried over anhydrous Na₂SO₄ and the solvent was removed to yield the product (97.25 g; 98% yield) as a white solid, mp 120.0–121.5 °C ¹H NMR (CDCl₃): δ 1.45(s, 9H), 3.00–3.20(m, 2H), 4.41–4.52(m, 1H), 5.05 (s, 2H), 5.22–5.30(s, 1H), 6.38(s, 1H), 7.08–7.38(m, 10H).

5.2.2. (RS)-tert-Butyl 2-(2-amino-3-phenylpropanoyl) hydrazinecarboxylate **2**

A solution of compound **1** (47.79 g; 116 mmol) in methanol (250 mL) was treated with 10% palladium on carbon (7.89 g). The

reaction mixture was stirred at room temperature under hydrogen (low pressure) for 3 h. The catalyst was filtered off, rinsed with methanol and the solvent was evaporated, leaving a crude product which was purified by recrystallization (ethyl acetate/hexanes) to yield the product as a white solid (26.53 g, 82% yield), mp 115.0–116.0 °C ¹H NMR (CDCl₃): δ 1.48 (s, 9H), 2.68–2.76 (dd, 1H, J = 15, 9 Hz), 3.28–3.36 (dd, 1H, J = 15, 6 Hz), 3.70–3.75 (dd, 1H, J = 9, 6 Hz), 6.45 (s, 1H), 7.20–7.36 (m, 5H).

5.2.3. (RS)-tert-Butyl 2-(2-(benzylamino)-3-phenylpropanoyl) hydrazinecarboxylate **3**

A solution of compound 2 (23.40 g; 83.8 mmol) and benzaldehyde (10.68 g; 100.6 mmol) in dry 1, 2-dichloroethane (150 mL) was treated with glacial acetic acid (7.05 g; 117.3 mmol), followed by sodium triacetoxyborohydride (25.56 g; 117.3 mmol). The reaction mixture was stirred for 4 h at room temperature and then neutralized via the dropwise addition of cold 10% aqueous NaOH solution to pH 9-10 while stirring. The organic phase was separated and the aqueous phase was extracted with ethyl acetate $(3 \times 150 \text{ mL})$, the combined organic extracts were dried over anhydrous Na₂SO₄ and the solvent removed. The crude product was purified by flash chromatography (silica gel/hexane/ethyl acetate) to yield a pure product as a colorless oil (14.04 g, 45% yield). ¹H NMR (CDCl₃): δ 1.45 (s, 9H), 2.74–2.82 (m, 1H), 3.19-3.24 (dd, 1H, J = 12, 6 Hz), 3.46-3.54 (dd, 1H, J = 9, 6 Hz), 3.54-3.58 (d, 1H, J = 12 Hz), 3.78-3.52 (d, 1H, J = 12 Hz), 6.82 (s, 1H), 7.08-7.32 (m, 10H).

5.2.4. (RS)-tert-Butyl 3,4-dibenzyl-5-oxoimidazolidin-1-yl (hydroxymethyl)carbamate **4**

A mixture of compound **3** (11.20 g; 30.31 mmol) and 37% aqueous formaldehyde (50 mL) was refluxed for 4 h. The reaction mixture was cooled to room temperature, water (50 mL) was added, and the solution was extracted with CH_2Cl_2 (3 × 70 mL). The organic phase was dried over anhydrous Na_2SO_4 and the solvent was removed in vacuo. The crude product was purified by flash chromatography (silica gel/hexane/ethyl acetate) to yield a pure product as a colorless oil (6.48 g; 52% yield). ¹H NMR (CDCl₃): δ 1.42 (s, 9H), 2.98–3.02 (m, 1H), 3.08–3.15 (m, 1H), 3.45–3.60 (m, 2H), 3.80–3.85 (s, 1H), 4.05 (s, 2H), 4.70–4.82 (m, 2H), 7.05–7.50 (m, 10H).

5.2.5. (RS)-tert-Butyl 3,4-dibenzyl-5-oxoimidazolidin-1ylcarbamate **5**

Compound **4** (12.47 g; 30.31 mmol) in 1, 4-dioxane (50 mL) was treated with a solution of KOH (29.68 g; 530 mmol) in H₂O (53 mL) and the reaction mixture was stirred at room temperature for 1 h. The solvent was removed on a rotary evaporator and the resulting residue was extracted with ethyl acetate (3×70 mL). The organic phase was dried over anhydrous Na₂SO₄ and the solvent was removed. The crude product was purified by flash chromatography (silica gel/hexane/ethyl acetate) to yield a pure product as a colorless oil (7.51 g; 65% yield). ¹H NMR (CDCl₃): δ 1.42 (s, 9H), 2.95–3.08

Table 1

N-Amino-4-imidazolidinone derivatives (I)^a



•				
Compound	P ₁	R ₂	R ₄	R ₅
7	benzyl	benzyl		Н
8	benzyl	benzyl	Ů, NH	Н
9	benzyl	benzyl	ОН	Н
10 ^b	benzyl	benzyl	S C NO	н
11 ^b	benzyl	benzyl		н
12 ^b	benzyl	benzyl	I CAN CO	н
13	benzyl	benzyl	Соон	н
14	benzyl	Н	NH NH	н
15	benzyl	Н	Он	Н
16 ^b	benzyl	Н	I CHO	н
17 ^b	benzyl	н	K → O N → F	Н

(continued on next page)

Table 1 (continued)							
Compound	P ₁	R ₂	R ₄	R ₅			
18	benzyl	Н	Соон	Н			
19	isobutyl	benzyl		Н			
20	isobutyl	benzyl	NH NH	Н			
21	isobutyl	benzyl	ОН	Н			
22	isobutyl	benzyl	ľ.	н			
23	isobutyl	benzyl	Соон	н			
24 ^b	isobutyl	benzyl	J H Jo	Н			
25	isobutyl	benzyl	-SO ₂ -CH ₃	-SO ₂ -CH ₃			
26	isobutyl	benzyl	-so ₂ -	-so ₂ -			

^a $R_3 = H$ for all.

^b Compounds were screened as diastereomeric mixtures.

(m, 1H), 3.12-3.22 (dd, 1H, J = 12, 6 Hz), 3.44-3.50 (d, 1H, J = 12 Hz), 3.54-3.58 (s, 1H), 3.78-3.86 (d, 1H J = 12 Hz), 3.96 (s, 1H), 4.02-4.12 (m, 1H), 6.30-6.42 (s, 1H), 7.10-7.22 (m, 10H).

5.2.6. (RS)-3-Amino-1,5-dibenzylimidazolidin-4-one 6

Compound **5** (10.53 g; 27.60 mmol) was dissolved in CH₂Cl₂ (300 mL) and silica gel (Sorbent Technologies, 60 Å, 32–63 μ m) (140 g) was added. The solvent was removed on a rotary evaporator and the dry powdered solid was irradiated in a microwave oven in an open crystallizing dish for 10 min at 860 W. The solid was thoroughly washed with methanol and the solvent was removed. The crude product was purified by flash chromatography (silica gel/hexane/ethyl acetate) to yield a pure product as a colorless oil (2.33 g; 30% yield). ¹H NMR (CDCl₃): δ 2.85–3.02 (m, 1H), 3.09–3.17 (dd, 1H, *J* = 12, 6 Hz), 3.38–3.46 (d, 1H, *J* = 12 Hz), 3.46–3.56 (m, 1H), 3.72–3.84 (m, 2H), 3.95–4.04 (d, 1H, *J* = 12 Hz), 7.08–7.18 (m, 10H).



Fig. 3. Inhibition of human neutrophil elastase and proteinase 3 by compounds **7–26**. Values were expressed as percent inhibition using an inhibitor/enzyme ratio of 500, and an incubation time of 30 min for human neutrophil elastase and no incubation for proteinase 3.

5.2.7. (RS)-Ethyl 2-(3-(3,4-dibenzyl-5-oxoimidazolidin-1-yl) ureido)acetate **7**

Compound **6** (0.56 g; 2 mmol) in dry CH₂Cl₂ (3 mL) was cooled to 0 °C and then treated with triethylamine (0.33 mL, 2.4 mmol) and ethyl isocyanatoacetate (0.26 g; 2 mmol). The reaction mixture was stirred overnight at room temperature. The mixture was treated with ethyl acetate (40 mL) and then washed successively with 5% aqueous HCl (10 mL), 5% aqueous NaHCO₃ (10 mL) and brine (10 mL). The organic phase was dried over anhydrous Na₂SO₄ and the solvent was removed. The crude product was purified by flash chromatography (silica gel/hexane/ethyl acetate) to yield a pure product as a colorless oil (0.15 g; 18%). ¹H NMR (CDCl₃): δ 1.20–1.28 (t, 3H, *J* = 6 Hz), 2.92–3.15 (m, 2H), 3.48–3.55 (d, 1H, *J* = 9 Hz), 3.55–3.61 (m, 1H), 3.75–3.92 (m, 3H), 4.00–4.19 (m, 4H), 5.80 (s, 1H), 7.15–7.28 (m, 10H); ¹³C NMR (CDCl₃): δ 173.37, 170.86, 156.88, 137.83, 137.22, 130.06, 129.78, 128.85, 128.64, 128.55, 128.52, 128.41, 127.71, 126.68, 69.65, 65.44, 61.51, 59.03, 41.94, 37.11, 14.27.

5.2.8. (RS)-1-(3,4-Dibenzyl-5-oxoimidazolidin-1-yl)-3-phenethylurea **8**

Prepared from compound **6** and 2-phenethyl isocyanate using a procedure similar to that used in the synthesis of compound **7** to give a pure product as a colorless oil (0.61 g; 72% yield). ¹H NMR (CDCl₃): δ 2.56–2.79 (m, 2H), 2.91–3.12 (m, 2H), 3.14–3.44 (m, 2H),



Fig. 4. Dixon plot for the interaction of compound 24 with human neutrophil elastase.

3.44–3.54 (d, 1H, J = 12 Hz), 3.51–3.63 (m, 1H), 3.80–4.00 (m, 3H), 4.64–4.78 (m, 1H), 6.64–6.76 (s, 1H), 7.00–7.44 (m, 15H); ¹³C NMR (CDCl₃): δ 173.05, 156.87, 139.07, 137.68, 137.11, 130.15, 128.99, 128.85, 128.72, 128.65, 128.39, 127.82, 126.79, 126.49, 69.72, 65.33, 58.87, 41.54, 37.01, 36.22.

5.2.9. (RS)-4-(3,4-Dibenzyl-5-oxoimidazolidin-1-ylamino)-4-oxobutanoic acid **9**

To compound **6** (0.56 g; 2 mmol) in dry CH₂Cl₂ (10 mL) was added succinic anhydride (0.20 g; 2 mmol) and the reaction mixture was stirred overnight at room temperature. The solvent was removed on a rotary evaporator and the crude product was washed with 20 mL diethyl ether to give a pure product as a white solid (0.54 g; 71% yield), mp 131.5–133.0 °C ¹H NMR (CDCl₃): δ 2.39–2.59 (m, 2H), 2.64–2.74 (m, 2H), 2.91–3.19 (m, 2H), 3.49–3.58 (d, 1H, J = 12 Hz), 3.56–3.64 (m, 1H), 3.73–3.82 (d, 1H, J = 12 Hz), 4.04–4.23 (m, 2H), 7.12–7.36 (m, 10H), 8.33–8.46 (s, 1H); ¹³C NMR (CD₃OD): δ 174.69, 172.41, 171.46, 137.59, 137.03, 129.67, 128.57, 128.36, 128.17, 127.44, 126.43, 68.61, 65.32, 58.95, 36.85, 28.63, 28.15.

5.2.10. (RS)-1-Benzyl-N-[(RS)-3,4-dibenzyl-5-oxoimidazolidin-1yl]-5-oxopyrrolidine-3-carbox-amide **10**

A solution of 1-benzyl-5-oxopyrrolidine-3-carboxylic acid (0.44 g; 2 mmol) dissolved in 20 mL DMF was treated with 1-(3dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.46 g; 2.4 mmol) and the solution was stirred for 20 min. Compound 6 (0.56 g: 2 mmol) was added and the reaction mixture was stirred at room temperature overnight. The solvent was removed in vacuo and the residue was dissolved in CH₂Cl₂ (70 mL) and then was washed sequentially with 5% aqueous HCl (3×20 mL), 5% aqueous NaHCO₃ (3×20 mL) and brine (3×20 mL). The organic phase was dried over anhydrous Na₂SO₄ and the solvent was removed. The crude product was purified by flash chromatography (silica gel/ hexane/ethyl acetate) to yield a pure product as a colorless oil (0.28 g; 29% yield). ¹H NMR (CDCl₃): δ 2.50–2.80 (m, 2H), 2.86–2.98 (m, 1H), 3.00–3.17 (m, 2H), 3.28–3.49 (m, 3H), 3.48–3.56 (m, 1H), 3.71-3.86 (m, 1H), 3.93-4.02 (t, 1H, J = 6 Hz), 4.02-4.11 (m, 1H), 4.30–4.42 (t, 2H, J = 6 Hz), 7.05–7.40 (m, 15H), 9.16–9.22 (d, 1H, J = 15 Hz; ¹³C NMR (CDCl₃): δ 172.75, 172.47, 171.77, 137.74, 137.09, 135.73, 129.79, 128.91, 128.75, 128.62, 128.43, 128.09, 127.89, 127.71, 126.69, 68.73, 65.29, 59.09, 49.08, 46.63, 37.09, 34.88, 34.56, 34.39.

5.2.11. (RS)-N-[(RS)-3,4-Dibenzyl-5-oxoimidazolidin-1-yl]-1-(4-fluorobenzyl)-5-oxopyrrolidine-3-carboxamide **11**

Prepared from compound **6** and 1-(4-fluorobenzyl)-5-oxopyrrolidine-3-carboxylic acid using a procedure similar to that used in the synthesis of compound **10** to give a pure product as a colorless oil (0.34 g; 34% yield). ¹H NMR (CDCl₃): δ 2.54–2.83 (m, 2H), 2.91–3.18 (m, 3H), 3.30–3.51 (m, 3H), 3.51–3.62 (m, 1H), 3.78–3.90 (t, 1H, *J* = 12 Hz), 3.97–4.12 (m, 2H), 4.27–4.51 (m, 2H), 6.94–7.08 (m, 2H), 7.12–7.40 (m, 12H), 7.66–7.80 (d, 1H, *J* = 24 Hz); ¹³C NMR (CDCl₃): δ 172.65, 172.61, 172.49, 172.43, 171.74, 164.04, 160.78, 137.68, 137.07, 137.04, 131.63, 131.59, 129.93, 129.82, 128.75, 128.66, 128.44, 127.78, 126.73, 115.96, 115.67, 68.74, 65.25, 58.99, 48.88, 45.93, 37.02, 34.83, 34.54.

5.2.12. (RS)-N-[(RS)-3,4-Dibenzyl-5-oxoimidazolidin-1-yl]-1-(furan-2-ylmethyl)-5-oxopyrrolidine-3-carboxamide **12**

Prepared from compound **6** and 1-(furan-2-ylmethyl)-5-oxopyrrolidine-3-carboxylic acid using a procedure similar to that used in the synthesis of compound **10** to give a pure product as a colorless oil (0.51 g; 40% yield). ¹H NMR (CDCl₃): δ 2.50–2.75 (m, 2H), 2.90–3.01 (m, 1H), 3.01–3.17 (m, 2H), 3.37–3.63 (m, 4H), 3.76–3.90 (m, 1H), 4.00–4.15 (m, 2H), 4.28–4.53 (m, 2H), 6.20–6.30 (m, 2H), 7.07–7.42 (m, 11H), 8.67–8.82 (d, 1H, J = 27 Hz); ¹³C NMR (CDCl₃): δ 172.63, 172.54, 171.78, 149.32, 142.80, 137.74, 137.11, 129.81, 128.78, 128.63, 128.45, 127.73, 126.71, 110.59, 108.90, 68.77, 65.33, 59.13, 49.16, 39.35, 37.09, 34.92, 34.51.

5.2.13. (RS)-2-(3,4-Dibenzyl-5-oxoimidazolidin-1-ylcarbamoyl) benzoic acid **13**

Prepared from compound **6** and phthalic anhydride using a similar procedure as that used in the synthesis of compound **9** to give a pure product as a white solid (0.47 g; 47% yield), mp 132.0–134.0 °C ¹H NMR (CDCl₃): δ 2.91–3.17 (m, 2H), 3.64–3.74 (m, 2H), 3.74–3.82 (d, 1H, *J* = 15 Hz), 4.29–4.40 (dd, 1H, *J* = 18, 6 HZ), 7.04–7.67 (m, 10H), 7.75–8.08 (m, 4H), 9.22(s, 1H); ¹³C NMR (CD₃OD): δ 172.51, 164.16, 163.66, 137.08, 136.61, 134.89, 134.86, 132.30, 130.68, 129.48, 129.45, 129.38, 128.82, 128.47, 128.33, 128.18, 128.18, 127.34, 126.35, 123.79, 123.77, 67.96, 64.74, 59.04, 36.65.

5.2.14. (RS)-1-(4-Benzyl-5-oxoimidazolidin-1-yl)-3-phenethylurea **14**

A solution of compound **8** (0.50 g; 1.2 mmol) in dry methanol (50 mL) was treated with 10% palladium on carbon (0.35 g) under hydrogen gas and the reaction mixture was stirred for 1 h at room temperature. The catalyst was filtered off and the solvent was removed on a rotary evaporator leaving a crude product which was washed with diethyl ether (2 × 5 mL) to yield a pure product as a white solid (0.23 g; 59% yield), mp 130.0–131.0 °C ¹H NMR (CDCl₃): δ 2.69–2.85(m, 2H), 2.92–3.14 (m, 2H), 3.33–3.43 (m, 2H), 3.70–3.82 (m, 1H), 4.04–4.15 (t, 1H, *J* = 9 Hz), 4.26–4.37 (dd, 1H, *J* = 12, 6 Hz), 4.98–5.13 (t, 1H, *J* = 9 Hz), 6.97–7.11 (s, 1H), 7.11–7.38 (m, 10H); ¹³C NMR (CDCl₃): δ 175.59, 156.93, 139.06, 136.95, 129.63, 129.03, 128.88, 128.75, 127.25, 126.64, 64.73, 59.28, 41.56, 36.82, 36.22.

5.2.15. (RS)-4-(4-Benzyl-5-oxoimidazolidin-1-ylamino)-4-oxobutanoic acid **15**

Prepared from compound **9** using a similar procedure as that of compound **14** to give a pure product as a light yellow oil (0.34 g; 89% yield). ¹H NMR (CDCl₃): δ 2.43–2.73 (m, 4H), 3.09–3.26 (m, 1H), 3.30–3.47 (m, 1H), 4.23–4.38 (m, 1H), 4.51–4.69 (m, 2H), 7.16–7.46 (m, 5H); ¹³C NMR (CD₃OD): δ 174.22, 171.94, 165.82, 133.83, 129.34, 129.03, 128.70, 128.61, 127.33, 57.67, 33.68, 28.45, 28.08, 26.08.

5.2.16. (RS)-1-Benzyl-N-[(RS)-4-benzyl-5-oxoimidazolidin-1-yl]-5-oxopyrrolidine-3-carboxamide **16**

Prepared from compound **10** using a similar procedure as that of compound **14** to give a pure product as a colorless oil (0.40 g; 65% yield). ¹H NMR (CDCl₃): δ 2.57–2.84 (m, 2H), 2.85–2.98 (m, 1H), 2.98–3.23 (m, 2H), 3.30–3.58 (m, 3H), 3.68–3.78 (m, 1H), 4.20–4.28 (m, 1H), 4.34–4.41 (m, 1H), 4.44–4.56 (m, 1H), 7.05–7.42 (m, 10H), 8.68–8.86 (d, 1H, *J* = 18 Hz); ¹³C NMR (CDCl₃): δ 174.90, 172.89, 171.69, 137.81, 137.02, 129.64, 129.41, 128.94, 128.75, 128.42, 128.07, 127.03, 126.64, 66.72, 59.11, 49.08, 46.68, 40.93, 36.56, 34.81.

5.2.17. (RS)-N-[(RS)-4-Benzyl-5-oxoimidazolidin-1-yl]-1-(4-fluorobenzyl)-5-oxopyrrolidine-3-carboxamide **17**

Prepared from compound **11** using a similar procedure as that of compound **14** to give a pure product as a colorless oil (0.29 g; 71% yield). ¹H NMR (CDCl₃): δ 2.63–2.82 (m, 2H), 2.90–3.04 (m, 1H), 3.04–3.21 (m, 23H), 3.34–3.57 (m, 2H), 3.73–3.81 (m, 1H), 4.21–4.34 (m, 1H), 4.34–4.53 (m, 2H), 6.93–7.07 (t, 2H, *J* = 9 Hz), 7.10–7.38 (m, 7H), 8.07–8.25 (d, 1H, *J* = 21 Hz); ¹³C NMR (CDCl₃): δ 171.79, 171.73, 164.09, 160.83, 136.92, 131.53, 129.96, 129.85, 129.68, 129.44, 128.83, 128.48, 127.13, 116.02, 115.74, 63.78, 59.16, 48.93, 46.02, 36.49, 34.86.

5.2.18. (RS)-2-(4-Benzyl-5-oxoimidazolidin-1-ylcarbamoyl)benzoic acid **18**

Prepared from compound **13** using a similar procedure as that of compound **14** to give a pure product as a light yellow solid (0.32 g; 81% yield), mp 123.5–125.0 °C ¹H NMR (DMSO): δ 2.66–2.80 (m, 1H), 2.92–3.06 (m, 1H), 3.15 (s, 1H), 3.51–3.63 (m, 1H), 4.00–4.16 (m, 1H), 4.22–4.34 (m, 1H), 7.12–7.40 (m, 5H), 7.42–7.74 (m, 4H), 7.07 (s, 1H), 10.43 (s, 1H); ¹³C NMR (CD₃OD): δ 173.01, 164.66, 164.16, 135.51, 134.50, 131.82, 131.36, 130.63, 130.19, 129.50, 128.51, 124.23, 65.24, 59.54, 37.15.

The compounds derived from Z-DL-Leu-OH (compounds **19–26**) were synthesized using procedures as those used in the synthesis of compounds **1–18**.

5.2.19. (RS)-Ethyl 2-(3-(3-benzyl-4-isobutyl-5-oxoimidazolidin-1yl)ureido)acetate **19**

White solid (50% yield), mp 114.0–115.5 °C ¹H NMR (DMSO): δ 0.68–0.90 (m, 6H), 1.10–1.24 (t, 3H, J = 9 Hz), 1.42–1.58 (m, 2H), 1.78–1.93 (m, 1H), 3.17–3.26 (m, 1H), 3.57–3.66 (d, 1H, J = 12 Hz), 3.80–3.95 (m, 3H), 3.97–4.14 (m, 3H), 4.22–4.30 (d, 1H, J = 6 Hz), 6.24–6.36 (t, 1H, J = 6 Hz), 7.12–7.36 (m, 5H), 8.05 (s, 1H); ¹³C NMR (CDCl₃): δ 175.49, 170.92, 156.76, 137.58, 129.14, 128.74, 127.87, 69.68, 62.75, 61.66, 59.45, 42.10, 39.08, 24.88, 23.17, 22.51, 14.33.

5.2.20. (RS)-1-(3-Benzyl-4-isobutyl-5-oxoimidazolidin-1-yl)-3-phenethylurea **20**

Oil (33% yield). ¹H NMR (DMSO): δ 0.75–0.98 (m, 6H), 1.46–1.64 (m, 2H), 1.84–1.98 (m, 1H), 2.67–2.82 (t, 2H, *J* = 9 Hz), 3.19–3.28 (m, 1H), 3.30–3.45 (m, 2H), 3.57–3.67 (d, 1H, *J* = 12 Hz), 3.90–4.00 (d, 1H, *J* = 12 Hz), 4.00–4.07 (d, 1H, *J* = 6 Hz), 4.23–4.51 (d, 1H, *J* = 6 Hz), 5.52–5.63 (t, 1H, *J* = 6 Hz), 7.08–7.42 (m, 10H), 7.72 (s, 1H); ¹³C NMR (CDCl₃): δ 175.15, 156.82, 139.03, 137.34, 129.08, 128.81, 127.97, 126.67, 69.74, 62.57, 59.22, 41.53, 39.17, 36.23, 24.87, 23.10, 22.63.

5.2.21. (RS)-4-(3-Benzyl-4-isobutyl-5-oxoimidazolidin-1-ylamino)-4-oxobutanoic acid **21**

Oil (52% yield). ¹H NMR (DMSO): δ 0.70–0.82 (m, 3H), 0.82–0.95 (m, 3H), 1.47–1.63 (m, 2H), 1.78–1.95 (m, 1H), 2.40–2.58 (m, 2H), 2.58–2.74 (m, 2H), 3.23–3.33 (m, 1H), 3.64–3.74 (d, 1H, *J* = 12 Hz), 3.90–3.98 (d, 1H, *J* = 12 Hz), 4.05–4.13 (d, 1H, *J* = 6 Hz), 4.28–4.35 (d, 1H, *J* = 6 Hz), 7.16–7.37 (m, 5H), 9.06 (s, 1H); ¹³C NMR (CDCl₃): δ 173.56, 172.79, 172.29, 137.50, 129.27, 129.19, 128.77, 128.69, 127.96, 67.40, 62.46, 59.89, 38.79, 26.91, 26.77, 24.91, 23.20, 22.21.

5.2.22. (RS)-N-(3-Benzyl-4-isobutyl-5-oxoimidazolidin-1-yl)-3-phenylpropanamide **22**

White solid (60% yield), mp 102.0–103.5 °C ¹H NMR (DMSO): δ 0.74–0.97 (m, 6H), 1.47–1.67 (m, 2H), 1.84–1.99 (m, 1H), 2.42–2.58 (t, 2H, J = 9 Hz), 2.84–2.98 (t, 2H, J = 9 Hz), 3.23–3.31 (m, 1H), 3.62–3.70 (d, 1H, J = 12 Hz), 3.89–3.98 (d, 1H, J = 12 Hz), 3.98–4.06 (d, 1H, J = 6 Hz), 4.17–4.24 (d, 1H, J = 6 Hz), 7.04–7.41 (m, 10H), 9.17 (s, 1H); ¹³C NMR (CDCl₃): δ 174.34, 171.11, 140.36, 137.72, 129.17, 128.85, 128.76, 128.57, 127.89, 126.69, 68.63, 62.69, 59.67, 39.01, 36.06, 31.32, 24.93, 23.23, 22.44.

5.2.23. (RS)-2-(3-Benzyl-4-isobutyl-5-oxoimidazolidin-1ylcarbamoyl)benzoic acid **23**

White solid (53% yield), mp 105.5–107.0 °C ¹H NMR (DMSO): δ 0.78–1.07 (m, 6H), 1.60–1.85 (m, 2H), 1.92–2.08 (m, 1H), 3.38–3.47 (m, 1H), 3.86–3.95 (d, 1H, *J* = 12 Hz), 4.04–4.12 (d, 1H, *J* = 12 Hz), 4.17–4.23 (d, 1H, *J* = 6 Hz), 4.52–4.59 (d, 1H, *J* = 6 Hz), 7.20–7.48 (m, 5H), 7.71–7.96 (m, 4H); ¹³C NMR (CDCl₃): δ 173.95, 164.77, 164.11, 137.82, 136.00, 135.03, 130.10, 130.01, 129.17, 128.66, 128.02, 125.94, 124.12, 68.09, 62.25, 59.87, 38.91, 24.93, 23.10, 22.45.

5.2.24. (RS)-Benzyl 1-((RS)-3-benzyl-4-isobutyl-5oxoimidazolidin-1-ylamino)-1-oxo-3-phenyl-propan-2ylcarbamate **24**

Oil (48% yield). ¹H NMR (DMSO): δ 0.73–0.85 (m, 3H), 0.85–0.98 (m, 3H), 1.47–1.66 (m, 2H), 1.84–1.96 (m, 1H), 2.92–3.17 (m, 2H), 3.20–3.28 (m, 1H), 3.57–3.68 (m, 1H), 3.78–3.86 (m, 1H), 3.86–3.99 (m, 2H), 3.99–4.08 (m, 1H), 4.85–5.06 (m, 2H), 7.05–7.40 (m, 10H), 8.64–8.80 (d, 1H, *J* = 24 Hz); ¹³C NMR (CDCl₃): δ 174.01, 170.35, 156.25, 137.79, 136.21, 129.81, 129.40, 129.21, 129.14, 128.53, 128.34, 127.37, 68.23, 67.60, 62.55, 59.55, 59.43, 39.20, 38.31, 24.52, 23.23, 22.67.

5.2.25. (RS)-N-(3-Benzyl-4-isobutyl-5-oxoimidazolidin-1-yl)-N-(methylsulfonyl)methanesulfon-amide **25**

White solid (38% yield), mp 88.0–89.5 °C ¹H NMR (DMSO): δ 0.77–1.03 (m, 6H), 1.48–1.73 (m, 2H), 1.83–2.03 (m, 1H), 3.24–3.35 (m, 1H), 3.36–3.50 (d, 6H, *J* = 9 Hz), 3.70–3.80 (d, 1H, *J* = 18 Hz), 3.88–3.97 (d, 1H, *J* = 18 Hz), 4.07–4.14 (d, 1H, *J* = 9 Hz), 4.45–4.53 (d, 1H, *J* = 9 Hz), 7.23–7.47 (m, 5H); ¹³C NMR (CDCl₃): δ 174.67, 137.33, 129.35, 128.90, 128.15, 69.25, 62.08, 59.77, 45.60, 45.05, 38.03, 24.95, 23.00, 22.26.

5.2.26. (RS)-N-(3-Benzyl-4-isobutyl-5-oxoimidazolidin-1-yl)-4methyl-N-tosylbenzenesulfon amide **26**

White solid (53% yield), mp 83.0–85.0 °C ¹H NMR (DMSO): δ 0.73–0.95 (m, 6H), 1.34–1.71 (m, 2H), 1.82–2.02 (m, 1H), 2.42 (s, 6H), 3.12–3.22 (m, 1H), 3.67–3.77 (d, 1H, *J* = 12 Hz), 3.84–3.93 (d, 1H, *J* = 12 Hz), 4.13–4.18 (d, 1H, *J* = 6 Hz), 4.44–4.56 (d, 1H, *J* = 6 Hz), 7.20–7.45 (m, 9H), 7.70–7.92 (m, 4H); ¹³C NMR (CDCl₃): δ 174.02, 146.06, 145.99, 137.37, 135.37, 135.27, 129.82, 129.79, 129.42, 129.30, 129.22, 128.78, 127.97, 69.03, 62.18, 59.77, 37.86, 24.78, 23.21, 22.26, 22.03.

5.3. Enzyme assay and inhibitory studies

5.3.1. Human neutrophil elastase (HNE)

In a typical inhibition experiment, 10 μ L of 7.0 μ M HNE was incubated with 10 μ L of 3.5 mM solution of inhibitor in DMSO ([inhibitor]/[enzyme] = 500), 970 μ L 0.1 M HEPES/0.5 M NaCl buffer, pH 7.25, at 25 °C. After 30 min, 10 μ L of 70 mM methoxysuccinyl-Ala-Ala-Pro-Val *p*-nitroanilide was added and the amount of active enzyme was determined by monitoring the release of *p*-nitroaniline at 410 nm for 2 min. A control (hydrolysis) containing 970 μ L 0.1 M HEPES/0.5 M NaCl buffer, pH 7.25, 10 μ L of 7.0 μ M HNE, and 10 μ L DMSO was run under the same conditions. The remaining activity of HNE was expressed as %remaining activity = (v/v_0) × 100 and is the average of duplicate or triplicate determinations.

5.3.2. Determination of inhibition constant (K_I) for compound **24** against HNE

The $K_{\rm I}$ of inhibitor **24** was determined using a Dixon plot [18]. Briefly, 970 µL 0.1 M HEPES buffer, pH 7.25, containing 0.5 M NaCl, was added in six cuvettes, followed by the sequential addition of 0, 2, 4, 6, 8 and 10 µL of 5 mM solution of inhibitor **24** in DMSO and 10, 8, 6, 4, 2, 0 µL DMSO for final inhibitor concentrations of 0–50 µM. 10 µL of 7.0 µM HNE and 10 µL of 35 mM substrate (methoxysuccinyl-Ala-Ala-Pro-Val p-nitroanilide) were added. The amount of active enzyme was determined by monitoring the release of *p*nitroaniline at 410 nm for 2 min. The experiment was repeated at a second substrate concentration (70 mM) and a Dixon plot was constructed by plotting 1/v versus [I] (Fig. 3).

5.3.3. Human neutrophil proteinase 3 (Pr 3)

Ten microliters of a 1.73 mM inhibitor solution in DMSO ([inhibitor]/[enzyme] = 500) and 20 μ L of 12.98 mM Boc-Ala-Ala-Nva-SBzl in

DMSO were added to a cuvette containing 940 μ L 0.1 M HEPES/0.5 M NaCl buffer, pH 7.25. After the solution was well mixed, 20 μ L of 32 mM 5,5'-dithio-bis(2-nitrobenzioc acid) in DMSO and 10 μ L of 3.45 μ M solution of proteinase 3 in 0.1 M phosphate/0.25 M NaCl buffer, pH 6.50, were added and the change in absorbance was monitored at 410 nm for 2 min. A control (hydrolysis) containing 940 μ L 0.1 M HEPES/0.5 M NaCl, pH 7.25, 10 μ L 3.40 μ M solution of proteinase 3, 20 μ L DMSO, 20 μ L of 16 mM 5,5'-dithio-bis(2-nitrobenzioc acid) in DMSO, and 20 μ L of 6.49 mM Boc-Ala-Ala-Nva-SBzl in DMSO was also run under the same condition. Determinations were performed in duplicate or triplicate and remaining activity was calculated as described for HNE.

Acknowledgements

Support of this work by the Heart and Blood Institute of the National Institutes of Health (HL 57788) is gratefully acknowledged.

References

- J.D. Maclay, R.A. Rabinovich, W. MacNee, Am. J. Respir. Crit. Care Med. 179 (2009) 533-541.
- [2] R.W. Senior, S.D. Shapiro, COPD: Epidemiology, Pathophysiology, and Pathogenesis in Fishman's Pulmonary Diseases and Disorders, third ed.. McGraw-Hill, NY, 1998, pp. 659–628.
- [3] R.M. Vandivier, N.F. Voelkel, J. Chron. Obstr. Pulmon. Dis. 2 (2005) 177-184.
- [4] A. Churg, J.L. Wright, Proc. Am. Thorac. Soc. 6 (2009) 550-552.
- [5] (a) W. MacNee, Proc. Am. Thor. Soc. 2 (2005) 50-60;
 (b) F. Luppi, P.S. Hiemstra, Am. J. Respir. Crit. Care Med. 175 (2007) 527-531;
- (c) T. Rangasamy, V. Misra, L. Zhen, C.G. Tankersley, R.M. Tuder, S. Biswal, Am. J. Physiol. 296 (2009) L888–L900.
 [6] (a) K. Aoshiba, N. Yokohori, A. Nagai, Am. J. Respir. Cell Mol. Biol. 28 (2003)
- 555–562; (b) R.M. Tuder, I. Petrache, J.A. Elias, N.F. Voelkel, P.M. Henson, Am. J. Respir. Cell Mol. Biol. 28 (2003) 551–554;

(c) I.K. Demedts, T. Demoor, K.R. Bracke, G.F. Joos, G.G. Brusselle, Respir. Res. 7 (2006) 53-62.

- [7] R.A. Stockley, D. Mannino, P.J. Barnes, Proc. Am. Thorac. Soc. 6 (2009) 524–526.
- [8] (a) O. Wiedow, U.J. Meyer-Hoffert, Int. Med. 257 (2005) 319-328;
- (b) C.T. Pham, Nat. Rev. Immunol. 6 (2006) 541–550.
 [9] (a) S.D. Shapiro, E.P. Ingenito, Am. J. Respir. Cell Mol. Biol. 32 (2005) 367–372;
- (b) P.J. Barnes, Pharmacol. Rev. 56 (2004) 515–548. [10] M. Mouded, E.E. Egea, M.J. Brown, S.M. Hanlon, A.M. Houghton, L.W. Tsai, E.
- P. Ingenito, S.D. Shapiro, Am. J. Respir. Cell Mol. Biol. 41 (2009) 407–414. [11] (a) C.M. Greene, N.G. McElvaney, Brit. J. Pharmacol. 158 (2009) 1048–1058;
- (a) C.M. Greene, N.G. McElvaney, Birt J. Friatmaton. 136 (2009) 1046–1036,
 (b) T.H. Hansel, P.J. Barnes, Lancet 374 (2009) 744–755.
 (12) Nerreal-true read is that of L Scherbter. Biochem Bioc
- [12] Nomenclature used is that of I. Schechter, A. Berger, Biochem. Biophys. Res. Comm. 27 (1967) 157–162 where S1, S2, S3,...Sn and S1', S2', S3',...Sn' correspond to the enzyme subsites on either side of the scissile bond. Each subsite accommodates a corresponding amino acid residue side chain designated P1, P2, P3, ...Pn and P1', P2', P3', ...Pn' of the substrate or (inhibitor). S1 is the primary substrate specificity subsite, and P1–P1' is the scissile bond.

[13] (a) B. Korkmaz, T. Moreau, F. Gauthier, Biochimie 90 (2008) 227–242;
(b) M. Fujinaga, M.M. Chernaia, R. Halenbeck, K. Koths, M.N.G. James, J. Mol. Biol. 261 (1996) 267–278;
(c) M. Wysocka, A. Lesner, K. Guzow, L. Mackiewicz, A. Legowska, W. Wiczk, K. Rolka, Anal. Biochem. 378 (2008) 208–215;
(d) C. Koehl, C.G. Knight, J.G. Bieth, J. Biol. Chem. 278 (2003) 12609–12612;
(e) E. Hajjar, B. Korkmaz, F. Gauthier, B.O. Brandsdal, V. Witko-Sarsat, N. J. Reuter, Med. Chem. 49 (2006) 1248–1260;
(f) B. Korkmaz, S. Attucci, E. Hazouard, M. Ferrandiere, M.L. Jourdan, M. Brillard-Bourdet, L. Juliano, F.J. Gauthier, Biol. Chem. 277 (2002) 39074–39081;
(g) B. Korkmaz, S. Attucci, T. Moreau, E. Godat, L. Juliano, F. Gauthier, Am. J. Respir. Cell Mol. Biol. 30 (2004) 801–807.
[14] L. Wei, X. Gan, J. Zhong, K.R. Alliston, W.C. Groutas, Bioorg. Med. Chem. 11 (2003) 5149–5153.

- [15] A.F. Abdel-Magid, K.G. Garson, B.D. Harris, C.A. Maryanoff, R.D. Shah, J. Org. Chem. 61 (1996) 3849–3862.
- [16] T. Apelqvist, D. Wensbo, Tetrahedron Lett. 37 (1996) 1471-1472.
- [17] Y. Li, D. Dou, G. He, G.H. Lushington, W.C. Groutas, Bioorg. Med. Chem. 17 (2009) 3536–3542.
- - B. Epp, R. Kuang, J.R. Hoidal, Med. Chem. Lett. 3 (1995) 375–381; (c) W.C. Groutas, L.S. Chong, R. Venkataraman, R. Kuang, J.B. Epp, N. Houser-Archield, H. Huang, J.R. Hoidal, Arch. Biochem. Biophys. 332 (1996) 335–340;

(d) W.C. Groutas, R. Kuang, S. Ruan, J.B. Epp, R. Venkataraman, T.M. Truong, Bioorg. Med. Chem. 6 (1998) 661-671;

(e) W.C. Groutas, J.B. Epp, S. Ruan, S. Yu, H. Huang, S. He, J. Tu, N.M. Schechter, J. Turbov, C.J. Froelisch, W.C. Groutas, J. Am. Chem. Soc. 121 (1999) 8128-8129;

- (f) R. Kuang, J.B. Epp, S. Ruan, L.S. Chong, R. Venkataraman, J. Tu, S. He, T. M. Truong, W.C. Groutas, Bioorg. Med. Chem. 8 (2000) 1005–1016;
 (g) S. He, R. Kuang, R. Venkataraman, J. Tu, T.M. Truong, H.-K. Chan, W. C. Groutas, Bioorg. Med. Chem. 8 (2000) 1713–1717;

(h) W.C. Groutas, S. He, R. Kuang, S. Ruan, J. Tu, H.-K. Chan, Bioorg. Med. Chem. 9 (2001) 1543-1548;

 W.C. Groutas, J.B. Epp, R. Kuang, S. Ruan, L.S. Chong, R. Venkataraman, J. Tu,
 S. He, H. Yu, Q. Fu, Y.-H. Li, T.M. Truong, N.T. Vu, Arch. Biochem. Biophys. 385 (2001) 162–169;

- (2001) 102–109,
 (j) W. Huang, Y. Yamamoto, Y. Li, D. Dou, K.R. Alliston, R.P. Hanzlik, W. C. Groutas, J. Med. Chem. 51 (2008) 2003–2008.
 [20] J.C. Powers, J.L. Asgian, O.D. Ekici, K.E. James, Chem. Rev. 102 (2002)
- 4639-4750.